210 related articles for article (PubMed ID: 36603732)
1. Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition.
Moloney C; Roy Chaudhuri T; Spernyak JA; Straubinger RM; Brougham DF
Acta Biomater; 2023 Mar; 158():611-624. PubMed ID: 36603732
[TBL] [Abstract][Full Text] [Related]
2. Multimodal Targeted Nanoparticle-Based Delivery System for Pancreatic Tumor Imaging in Cellular and Animal Models.
Medina OP; Tower RJ; Medina TP; Ashkenani F; Appold L; Bötcher M; Huber L; Will O; Ling Q; Hauser C; Rohwedder A; Heneweer C; Peschke E; Hövener JB; Lüdtke-Buzug K; Boretius S; Mentlein R; Kairemo K; Glüer CC; Sebens S; Kalthoff H
Curr Pharm Des; 2022; 28(4):313-323. PubMed ID: 32679012
[TBL] [Abstract][Full Text] [Related]
3. Ultrasmall superparamagnetic iron oxide (USPIO)-based liposomes as magnetic resonance imaging probes.
Frascione D; Diwoky C; Almer G; Opriessnig P; Vonach C; Gradauer K; Leitinger G; Mangge H; Stollberger R; Prassl R
Int J Nanomedicine; 2012; 7():2349-59. PubMed ID: 22661890
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Spiers L; Gray M; Lyon P; Sivakumar S; Bekkali N; Scott S; Collins L; Carlisle R; Wu F; Middleton M; Coussios C
BMC Cancer; 2023 Sep; 23(1):896. PubMed ID: 37741968
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
6. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
7. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence Lifetime Nanoscopy of Liposomal Irinotecan Onivyde: From Manufacturing to Intracellular Processing.
Bernardi M; Signore G; Moscardini A; Pugliese LA; Pesce L; Beltram F; Cardarelli F
ACS Appl Bio Mater; 2023 Oct; 6(10):4277-4289. PubMed ID: 37699572
[TBL] [Abstract][Full Text] [Related]
9. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer.
Palchetti S; Caputo D; Digiacomo L; Capriotti AL; Coppola R; Pozzi D; Caracciolo G
Pharmaceutics; 2019 Jan; 11(1):. PubMed ID: 30650541
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D
Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000
[TBL] [Abstract][Full Text] [Related]
11. Advances in nano-delivery systems for doxorubicin: an updated insight.
Kanwal U; Irfan Bukhari N; Ovais M; Abass N; Hussain K; Raza A
J Drug Target; 2018 Apr; 26(4):296-310. PubMed ID: 28906159
[TBL] [Abstract][Full Text] [Related]
12. Effect of Composition and Size on Surface Properties of Anti-Cancer Nanoparticles.
Mishra I; Garrett M; Curry S; Jameson J; Kastellorizios M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686222
[TBL] [Abstract][Full Text] [Related]
13. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
14. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Lamb YN; Scott LJ
Drugs; 2017 May; 77(7):785-792. PubMed ID: 28401446
[TBL] [Abstract][Full Text] [Related]
15. Formation of hydrated PEG layers on magnetic iron oxide nanoflowers shows internal magnetisation dynamics and generates high in-vivo efficacy for MRI and magnetic hyperthermia.
McKiernan EP; Moloney C; Chaudhuri TR; Clerkin S; Behan K; Straubinger RM; Crean J; Brougham DF
Acta Biomater; 2022 Oct; 152():393-405. PubMed ID: 36007780
[TBL] [Abstract][Full Text] [Related]
16. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
Gilabert-Oriol R; Ryan GM; Leung AWY; Firmino NS; Bennewith KL; Bally MB
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261606
[TBL] [Abstract][Full Text] [Related]
17. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties.
Huang Z; Szoka FC
J Am Chem Soc; 2008 Nov; 130(46):15702-12. PubMed ID: 18950160
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Heating Stimulated Cargo Release with Dose Control using Multifunctional MR and Thermosensitive Liposome.
Ray S; Cheng CA; Chen W; Li Z; Zink JI; Lin YY
Nanotheranostics; 2019; 3(2):166-178. PubMed ID: 31183312
[No Abstract] [Full Text] [Related]
19. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
[TBL] [Abstract][Full Text] [Related]
20. Delineating the tumour microenvironment response to a lipid nanoparticle formulation.
Ngai J; MacMillan P; Kingston BR; Lin ZP; Ouyang B; Chan WCW
J Control Release; 2023 Jan; 353():988-1001. PubMed ID: 36516899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
